U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk’s (NYSE: NVO) highly in-demand drugs for diabetes […]
US Minority Veterans Face Unequal Access to Ozempic and Wegovy, Study Finds Read More »
LONDON – Novo Nordisk’s (NYSE: NVO) sales growth next year could be in the high teens in percentage terms, Chief
Novo Nordisk CFO Forecasts High-Teens Sales Growth for 2025 Read More »
COPENHAGEN – Novo Nordisk (NYSE: NVO) is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States
Novo Nordisk Lifts Curbs on Wegovy Prescriptions in the US, CEO Says Read More »
COPENHAGEN – On Wednesday, Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug, reassuring investors worried that
Novo Nordisk Stock Jumps as Q3 Wegovy Sales Top Estimates Read More »
LONDON – On Wednesday, Novo Nordisk (NYSE: NVO) chief financial officer Karsten Munk Knudsen said the company was aware of
Novo Nordisk is Aware of 10 Deaths From Compounded Weight-Loss Drug Copies Read More »
Americans are still eagerly seeking prescriptions for Eli Lilly’s (NYSE: LLY) and Novo Nordisk’s (NYSE: NVO) weight-loss and diabetes drugs
Americans Seeking Weight-Loss Drugs Face Supply and Insurance Hurdles Read More »
BRUSSELS/LONDON – EU antitrust regulators will decide by December 6 whether to clear Novo Holdings’ acquisition of contract drug manufacturer
EU Regulators Set Deadline for Decision on Novo Holdings’ Catalent Acquisition Read More »
NEW YORK – Most U.S. states do not currently cover highly sought-after weight-loss drugs from Novo Nordisk (NYSE: NVO) and
US Medicaid Programs Say Cost a Key Factor for Weight-Loss Drug Coverage, Survey Finds Read More »
On Monday, Novo Nordisk (NYSE: NVO) said an oral version of its drug semaglutide, helped significantly reduce the risk of
Novo Nordisk’s Oral Diabetes Drug Reduces Heart-Related Risks by 14% in Study Read More »
Copyright © 2024 abbonews.com
